Top Page
IDT Australia Limited
(Sydney:IDT)
IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)
IDT Australia Limited Business Overview & Revenue Model
IDT Australia Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.77M | 19.77M | 13.23M | 6.93M | 12.11M | 15.99M |
| Gross Profit | 9.69M | 9.69M | 10.42M | -3.53M | 2.82M | 4.88M |
| EBITDA | -6.54M | -6.54M | -5.56M | -8.83M | -340.00K | 2.75M |
| Net Income | -8.06M | -8.06M | -5.41M | -8.50M | -1.16M | 2.10M |
Balance Sheet | ||||||
| Total Assets | 36.92M | 36.92M | 31.37M | 28.29M | 30.08M | 34.13M |
| Cash, Cash Equivalents and Short-Term Investments | 4.11M | 4.11M | 904.00K | 4.43M | 9.21M | 6.93M |
| Total Debt | 10.40M | 10.40M | 4.47M | 740.00K | 881.00K | 766.00K |
| Total Liabilities | 15.03M | 15.03M | 7.93M | 4.15M | 3.46M | 6.51M |
| Stockholders Equity | 21.89M | 21.89M | 23.44M | 24.14M | 26.63M | 27.61M |
Cash Flow | ||||||
| Free Cash Flow | -7.55M | -7.55M | -10.30M | -8.42M | 1.95M | -156.00K |
| Operating Cash Flow | -6.25M | -6.25M | -9.60M | -7.90M | 2.86M | 370.00K |
| Investing Cash Flow | -4.50M | -4.50M | -1.09M | -522.00K | -912.00K | -526.00K |
| Financing Cash Flow | 10.75M | 10.75M | 6.77M | 3.64M | 337.00K | 224.00K |
IDT Australia Limited Technical Analysis
IDT Australia Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$41.75M | 11.67 | 7.64% | 3.23% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$43.89M | ― | -289.70% | ― | -4.27% | 33.91% | |
46 Neutral | AU$77.73M | 690.00 | 0.19% | ― | 17.82% | ― | |
41 Neutral | AU$19.03M | -1.28 | ― | ― | -47.30% | 82.53% | |
39 Underperform | AU$24.81M | -3.16 | -35.58% | ― | 45.30% | -24.18% |
IDT Australia Limited Corporate Events
IDT Australia Limited has announced a strategic realignment to focus on higher-return core business activities, resulting in anticipated annual cost savings of approximately $1 million for FY26. The company is shifting its Specialty Orals vertical towards radiopharmaceuticals, supported by recent contract wins, while maintaining its presence in clinical-stage innovations. Despite a Q1 EBITDA loss of $0.3 million, IDT reported a revenue increase of 18.2% from its three verticals compared to the previous year, driven by strong market demand and new contracts worth $3.4 million. This strategic shift aims to enhance profitability and leverage the company’s operational strengths.
IDT Australia Limited has announced its Annual General Meeting (AGM) scheduled for 19 November 2025, which will be conducted as a hybrid meeting allowing both in-person and virtual attendance. This meeting is significant for shareholders as it provides an opportunity to engage with the company’s board and participate in decision-making processes, reflecting IDT’s commitment to transparency and shareholder involvement.
IDT Australia Limited announced the cessation of 55,000 ordinary fully paid securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation may impact the company’s capital structure and could have implications for its financial strategy and stakeholder interests.
IDT Australia Limited has issued 348,400 Ordinary Shares without disclosure to investors under the Corporations Act, confirming compliance with relevant provisions and indicating no undisclosed ‘excluded information’. This move reflects IDT’s strategic financial maneuvers to potentially enhance its market positioning and operational capabilities, impacting stakeholders by maintaining transparency and regulatory adherence.
IDT Australia Limited has announced the quotation of 348,400 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and provide liquidity options for its stakeholders, potentially impacting its operational dynamics and investor relations.
IDT Australia Limited has announced the issuance of unquoted equity securities in the form of performance rights under an employee incentive scheme. The securities, which are not intended to be quoted on the ASX, include 262,686 performance rights vesting on August 31, 2025, 538,108 vesting on September 30, 2027, and 459,695 vesting on September 30, 2026. This move is likely aimed at incentivizing employees and aligning their interests with the company’s long-term goals.
IDT Australia Limited has announced the issuance of 634,304 fully paid ordinary shares to employees as a short-term incentive under the company’s LR 7.1 Placement Capacity. These shares, issued for nil consideration, are subject to a three-year on-sale restriction, reflecting the company’s strategy to incentivize and retain its workforce while potentially enhancing its market position.
IDT Australia Limited reported a 41% increase in revenue for FY25, reaching $20 million, marking the successful completion of the first stage of its strategic transformation program, the ‘Rebuild Strategy’. The company experienced significant growth in its Advanced Therapies vertical, with revenue surging 361% due to high demand for ADCs and mRNA technologies. Despite a net loss of $8.1 million, IDT is focusing on achieving positive cash flow and profitability in the next phase of its transformation, the ‘Sustainability Strategy’. The company aims to leverage its robust sales pipeline and recent contract wins to drive future growth.
IDT Australia Limited has released its corporate governance statement for the financial year ending June 30, 2025, as required by ASX Listing Rules. The statement, which is available on the company’s website, outlines the extent to which IDT Australia has adhered to the ASX Corporate Governance Council’s principles and recommendations. This disclosure is crucial for stakeholders as it provides transparency on the company’s governance practices, potentially impacting investor confidence and the company’s market positioning.
IDT Australia Limited reported a 40.6% increase in revenues to $19,861,000 for the year ending June 30, 2025. However, the company also experienced a 49% increase in losses, amounting to $8.1 million, compared to the previous year. No dividends were declared for the current or previous financial periods. The company’s net tangible assets per ordinary security decreased from 6.67 cents to 5.09 cents. The financial statements were audited with an unmodified opinion, and the Annual General Meeting is scheduled for November 19, 2025.
IDT Australia Limited has announced the planned retirement of its Chief Financial Officer, Mahendran Vasanthakumar, at the end of the month, marking the end of a four-decade career in finance and accounting. This transition is part of a broader restructuring of the company’s finance department, with Malika Perera appointed as the new Head of Finance. Perera brings over two decades of experience in senior financial, commercial, and operational roles across the pharmaceuticals, manufacturing, and distribution sectors. This change is expected to support IDT’s ongoing transformation and strategic initiatives.
IDT Australia Limited has announced the resignation of its CEO, Mr. Paul McDonald, with Mr. Mark Simari stepping in as Executive Chair to ensure business continuity. Despite a 40.6% increase in revenue to $19.9 million for FY25, the company reported a net loss of $7.5 million, partly due to bad debts. The company remains committed to its transformation program and will conduct a comprehensive review of its operations under new leadership to restore profitability.
IDT Australia Limited has requested a trading halt on its securities as it prepares to announce a change in management. This halt will remain in effect until the start of normal trading on August 7, 2025, or until the company releases its announcement. The trading halt is intended to allow IDT to finalize details related to the management change, ensuring that stakeholders are informed appropriately.